JP2024545183A5 - - Google Patents
Info
- Publication number
- JP2024545183A5 JP2024545183A5 JP2024534647A JP2024534647A JP2024545183A5 JP 2024545183 A5 JP2024545183 A5 JP 2024545183A5 JP 2024534647 A JP2024534647 A JP 2024534647A JP 2024534647 A JP2024534647 A JP 2024534647A JP 2024545183 A5 JP2024545183 A5 JP 2024545183A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- nucleic acid
- raav
- particles
- expression construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163288520P | 2021-12-10 | 2021-12-10 | |
| US63/288,520 | 2021-12-10 | ||
| PCT/US2022/081323 WO2023108159A1 (en) | 2021-12-10 | 2022-12-09 | Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024545183A JP2024545183A (ja) | 2024-12-05 |
| JP2024545183A5 true JP2024545183A5 (enExample) | 2025-12-17 |
Family
ID=86731334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024534647A Pending JP2024545183A (ja) | 2021-12-10 | 2022-12-09 | ウイルスベクターによりｂａｇ－３関連心筋症を処置するための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250041453A1 (enExample) |
| EP (1) | EP4444364A1 (enExample) |
| JP (1) | JP2024545183A (enExample) |
| KR (1) | KR20240118855A (enExample) |
| AU (1) | AU2022407655A1 (enExample) |
| CA (1) | CA3242351A1 (enExample) |
| IL (1) | IL313427A (enExample) |
| WO (1) | WO2023108159A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4493702A4 (en) * | 2022-03-18 | 2026-04-01 | Univ Florida | METHODS AND COMPOSITIONS FOR TREATING TNNT2-RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR |
| IL322735A (en) * | 2023-02-13 | 2025-10-01 | Astrazeneca Ireland Ltd | Nucleic acids encoding BCL2-associated athenogen 3 (BAG3) for gene therapy |
| WO2024215655A1 (en) * | 2023-04-10 | 2024-10-17 | Tenaya Therapeutics, Inc. | Cardioprotective bag3 therapies |
| WO2024229259A1 (en) * | 2023-05-02 | 2024-11-07 | Research Institute At Nationwide Children's Hospital | Gene therapy for treatment of protein misfolding diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015117010A2 (en) * | 2014-01-31 | 2015-08-06 | Temple University Of The Commonwealth System Of Higher Education | Bag3 as a target for therapy of heart failure |
| WO2015153889A2 (en) * | 2014-04-02 | 2015-10-08 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of latent viral infection |
| WO2017191274A2 (en) * | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| WO2018129528A1 (en) * | 2017-01-09 | 2018-07-12 | Duke University | Methods for treating ischemic injury |
| DK3906066T5 (da) * | 2019-01-04 | 2024-08-05 | Ultragenyx Pharmaceutical Inc | Geneterapikonstruktioner til behandling af wilsons sygdom |
| WO2021154923A2 (en) * | 2020-01-29 | 2021-08-05 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
-
2022
- 2022-12-09 CA CA3242351A patent/CA3242351A1/en active Pending
- 2022-12-09 IL IL313427A patent/IL313427A/en unknown
- 2022-12-09 WO PCT/US2022/081323 patent/WO2023108159A1/en not_active Ceased
- 2022-12-09 AU AU2022407655A patent/AU2022407655A1/en active Pending
- 2022-12-09 EP EP22905439.0A patent/EP4444364A1/en active Pending
- 2022-12-09 JP JP2024534647A patent/JP2024545183A/ja active Pending
- 2022-12-09 US US18/717,532 patent/US20250041453A1/en active Pending
- 2022-12-09 KR KR1020247023092A patent/KR20240118855A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024545183A5 (enExample) | ||
| US20220331409A1 (en) | Factor ix gene therapy | |
| JP2022500066A5 (enExample) | ||
| JP2024545186A5 (enExample) | ||
| JP6573991B2 (ja) | 血管性浮腫の治療としてのｃ１ｅｉのアデノ随伴ウイルス介在性送達 | |
| JP2021531752A5 (enExample) | ||
| JP2023524291A5 (enExample) | ||
| JP2024523707A5 (enExample) | ||
| JP2020518268A5 (enExample) | ||
| JP2022530824A5 (enExample) | ||
| JP2024513907A5 (enExample) | ||
| JP2025509828A5 (enExample) | ||
| JP2021500922A5 (enExample) | ||
| JP2023503850A5 (enExample) | ||
| JP2024546103A5 (enExample) | ||
| JP2024119900A (ja) | 優性遺伝性カテコラミン誘発多形性心室頻拍の治療のための組成物および方法 | |
| JP2020510433A5 (enExample) | ||
| JP2024527742A5 (enExample) | ||
| US11517631B2 (en) | Factor IX encoding nucleotides | |
| US12415850B2 (en) | Compositions and methods for regulating production of an antibody like protein and ribonucleic acid | |
| JP2022514271A5 (enExample) | ||
| JP2025503868A5 (enExample) | ||
| JP2024500786A5 (enExample) | ||
| RU2021121087A (ru) | Способы и композиции для лечения болезней накопления гликогена | |
| JP2020536519A5 (enExample) |